

Center for Vaccine  
Ethics and Policy



**Vaccines and Global Health: The Week in Review**  
**03 February 2024 :: Issue 736**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director*

*Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

***Contents [click to move among sections]***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

*:: [Pre-Print Servers](#)*

*:: [Think Tanks](#)*

## ***Milestones, Perspectives***

.....  
.....

### **WHO – 154th session of the Executive Board**

The 154th session of the Executive Board takes place on **22–27 January 2024**. Proceedings were webcast from [this page](#) which now includes recordings of all sessions.

*Main Documents page:* [https://apps.who.int/gb/e/e\\_eb154.html](https://apps.who.int/gb/e/e_eb154.html)

.....

### **WHO Director-General's opening on Gaza, the WHO Executive Board...- 31 January 2024**

31 January 2024

*[Excerpts]*

===

Last week, WHO's Executive Board met to discuss many aspects of the Organization's work.

Among other issues, the Board reviewed WHO's global strategic plan for the next four years, and approved the first WHO Investment Round, which we will hold later this year, and which aims to generate more predictable, flexible and sustainable funding for WHO's work.

Member States also discussed WHO's work on health emergencies, including pandemic prevention, preparedness and response.

They expressed **strong support for the pandemic agreement and amendments to the International Health Regulations**, and emphasised the urgency of concluding negotiations in time for the World Health Assembly in May of this year. It's vital that Member States meet that deadline.

Yesterday, a group of more than **40 global health leaders published an open letter calling on world leaders to show leadership, urgency and commitment to conclude a pandemic agreement** that transcends business as usual. I echo that call. One of the main purposes of the agreement is to improve equitable access to vaccines, tests, treatments and other products.

During the COVID-19 pandemic, WHO established COVAX and the COVID-19 Technology Access Pool, or C-TAP, to facilitate sharing of intellectual property, knowledge and innovations.

**COVAX closed at the end of last year, and today we are pleased to announce that C-TAP will become the Health Technology Access Pool, HTAP, with a broader mission to expand access to lifesaving tools for COVID-19 and other priority diseases.**

We're also pleased to announce that WHO and the Medicines Patent Pool have agreed a license agreement with the company SD Biosensor for the rights, know-how and material to manufacture its rapid diagnostic technology.

===

.....  
.....

## [WHO benchmarks for strengthening health emergency capacities](#)

25 January 2024 | Publication

### *Overview*

The updated [WHO Benchmarks for Strengthening Health Emergency Capacities](#) was published to **support the implementation of the International Health Regulations (IHR) and the health emergency prevention, preparedness, response and resilience capacities.**

Taking on board the lessons from the COVID-19 pandemic and other recent health emergencies, the benchmarks expanded to reflect closer alignment with [International Health Regulations 2005 \(IHR\) monitoring and evaluation framework](#), the [health systems for health security framework](#), [disaster risk management](#), and the [health emergency prevention, preparedness, response and resilience \(HEPR\) framework](#).

Benchmarking is a strategic process often used by businesses and institutes to standardize performance in relation to the best practices of their sector. The World Health Organization (WHO) and partners have developed **a tool with a list of benchmarks and corresponding suggested actions that can be applied to implement the International Health Regulations 2005 (IHR) and strengthen health emergency prevention, preparedness, response and resilience capacities.**

The first edition of the benchmarks was published in 2019 to support countries in developing, implementing and documenting progress of national IHR or health security plans (e.g. national action plan for health security (NAPHS), national action plan for emerging infectious diseases, public health emergencies and health security and other country level plans for health emergencies). **The tool has been updated to incorporate lessons from COVID-19 and other health emergencies**, to align with the updated IHR monitoring & evaluation framework (IHR MEF) tools and the health systems for health security framework, and to support strengthening health emergency prevention, preparedness, response and resilience (HEPR) capacities and the Preparedness and Resilience for Emerging Threats (PRET) initiative.

.....  
.....

### **Featured Analysis**

#### [A New Playbook for Gavi: Advancing Equitable and Sustainable Immunization in an Evolving Global Landscape](#)

*POLICY PAPERS -- Center for Global Development*

Orin Levine et al.

January 30, 2024

For nearly 25 years, Gavi has delivered impact and value for money and remained one of the most successful global health initiatives.

#### **Gavi's success has been driven by its use of three primary levers:**




- (1) accelerating new vaccine introductions,
- (2) increasing equitable immunization coverage, and
- (3) utilizing eligibility criteria to target support to the most impactful geographies.

For Gavi to be as successful going forward, its leadership and board need to reevaluate and adjust its operational model.

**Several imminent disruptions are exerting pressure on Gavi's ability to deliver results across these three levers.** For the upcoming 2026-2030 strategic period (known as "Gavi 6.0"),

**Gavi should adopt a new playbook** to leverage its strengths, mitigate the impacts of disruptions associated with these levers, and enable greater agility and effectiveness in its model.

**TABLE 2. Summary of the strengths and challenges motivating the proposed policy recommendations for Gavi 6.0**

Impact levers	Gavi's track record to date	Challenges on the horizon	Policy recommendations for 6.0
 <b>Introductions</b>	Largely successful in accelerating new vaccine adoption at scale	Next wave of highly impactful new vaccines requires immunization platforms that reach beyond infants to include two-year-olds and adolescents	Incorporate second year of life and adolescent platform strengthening as an explicit objective for Gavi 6.0
		Countries are demanding more say in setting priorities following vaccine inequities that occurred during the COVID-19 pandemic	Replace existing financing arrangements with an envelope financing approach that is driven by local priorities
		Vaccine security is focusing increasingly on regional manufacturing and procurement mechanisms	Recalibrate the global-regional balance in vaccine manufacturing and procurement
		Increasing overlap across global health mechanisms in specific disease areas may distort funding priorities and complicate country programming	Create a mechanism across Gavi and other global health initiatives to assure integrated approaches to disease control that optimize value for money and simplify implementation for countries
 <b>Coverage</b>	Investments in broader systems development have generated less impact in fragile and conflict-affected settings	The number of displaced people living in fragile and conflict-affected settings is likely to increase	Establish a stand-alone subsidiary that operates in fragile and conflict-affected settings with high-risk appetite
	Market shaping capabilities have successfully helped fill specific gaps in health systems infrastructure	Critical gaps in delivery systems infrastructure	Leverage Gavi's experience, including in market shaping, to accelerate innovations for immunization systems and primary health care more broadly
 <b>Eligibility</b>	Transition, eligibility, and co-financing model has supported progress on self-financing	Eligibility model is not well aligned with fiscal realities and disease burdens	Revise Gavi's eligibility policy to better align with countries' ability to pay and disease burdens

We offer seven policy recommendations for Gavi's board as it sets the course for Gavi 6.0. These include:

- (1) revising Gavi's eligibility policy to better align with countries' abilities to pay and disease burdens;
- (2) recalibrating the global-regional balance in vaccine manufacturing and procurement;
- (3) creating a mechanism across Gavi and other global health initiatives to assure integrated approaches to disease control that optimize value for money and simplify implementation for countries;
- (4) leveraging Gavi's experience, including in market shaping, to accelerate innovations for immunization systems and primary health care more broadly;
- (5) replacing existing financing arrangements with an envelope financing approach that is driven by local priorities;
- (6) establishing a stand-alone subsidiary that operates in fragile and conflict-affected settings with high-risk appetite; and
- (7) incorporating second year of life and adolescent platform building as an explicit objective for Gavi 6.0.



### **[The Technical Advisory Group on the Responsible Use of the Life Sciences and Dual-Use Research meets for the first time - WHO](#)**

30 January 2024 *Departmental news*

The Technical Advisory Group on the Responsible Use of the Life Sciences and Dual-Use Research (TAG-RULS DUR) was established in November 2023 to provide independent advice to WHO including **technical and strategic advice relevant to the monitoring and mitigation of biorisks, advances in the life sciences and related technologies, the governance of dual-use research and the responsible use of the life sciences.**

The TAG-RULS DUR members have expertise in a range of areas including, but not limited to, the following:

- oversight of dual-use research and dual-use of concern (DURC), knowledge, information, methods, products or technologies;
- biorisk mitigation and management, biosafety and biosecurity;
- emerging areas of research and technologies in biology and the life sciences (for example, but not limited to, synthetic biology, genome editing, virology, infectious diseases, bioinformatics, neurosciences) and associated disciplines (for example, but not limited to, chemistry, artificial intelligence, nanotechnologies);
- governance of emerging technologies;
- risk communication and disinformation;
- ethics, international law, policy and governance and other relevant social science domains, related to the responsible use of the life sciences, dual-use research and pandemic prevention, preparedness and response;
- foresight;
- monitoring and evaluation related to global health security; and
- One Health approach to the responsible use of the life sciences and dual-use research.

The composition of the TAG respects an adequate distribution of technical expertise, geographic and gender distribution. The members serve in their personal capacities, from a broad range of disciplines relevant to the TAG-RULS DUR areas of work.

This meeting, held on 24 January 2024, provided the opportunity to meet virtually for the first time; to discuss the current and upcoming project activities on the responsible use of the life sciences and dual-use research; and to share members' perspectives and priorities on the work ahead. A report of this meeting will be published.



## Featured Analysis

### [IFRC Global COVID-19 study: vaccine bank an 'essential element' of next pandemic response](#)

31/01/2024 | *Press release*

**Governments need to prepare for the next pandemic by establishing an international 'vaccine bank' which ensures the availability and distribution of vaccines equitably in all regions of the world.**

That's the central recommendation of a [new report](#) following a huge study into the impact of COVID-19 and authorities' reactions to it. The report is being released exactly four years on from the IFRC's first Global COVID emergency appeal, on 31st January 2020.

The International Federation of the Red Cross and Red Crescent (IFRC) commissioned researchers from the Humanitarian Observatory, an IFRC reference centre hosted by the Argentine Red Cross, to carry out a major research project. For it, they carried out **interviews with 16,027 people, working in collaboration with 90 Red Cross and Red Crescent National Societies.**

People from different sectors were asked about their experiences during the COVID-19 pandemic. Strategic partners from the private sector and trade unions also collaborated in conducting the surveys.

**Participants were chosen to represent people working or active in six societal sectors - healthcare, academia/education, transport, non-governmental organisations (NGOs), the corporate sector and the media.** The study looked for both common trends and contrasts across geographies and sectors. Its aim was to develop recommendations so that the next pandemic can be handled better than the last.

#### **The study – 'Insights Gained by Strategic Sectors During the Pandemic' – found:**

- Nearly 70% of people in all sectors and regions had a high fear of catching COVID-19. People in the Americas and/or working in healthcare had the highest fear.
- More than half of all respondents said their personal finances were affected by the pandemic.
- 54% of participants interviewed said their government handled the pandemic well. The percentage was highest across Africa and lowest across the Americas.
- Almost half of all respondents working in healthcare and the media felt 'discriminated against' for the role they played during the pandemic.
- The vast majority of interviewees said they received no priority for vaccinations despite the important roles they played during the pandemic.

#### **The main recommendations of the report include:**

- Creating a global vaccine and antidote bank to ensure the availability and distribution of supplies equitably in all regions.
- Establishing priorities for vaccination or delivery of medicines to those who enable the world's citizens to receive food, medical care, news and education.

- Carrying out a communication campaign from a supranational body that values the actions of the essential sectors to legitimise their tasks and recognize their work.



## **Polio – PHEIC**

### **Polio this week as of 31 Jan 2024 - GPEI**

#### ***Summary of new polioviruses this week, cases and positive environmental isolates:***

- Angola: one cVDPV2-positive environmental sample
- Benin: one cVDPV2-positive environmental sample
- Chad: two cVDPV2 cases
- Côte d’Ivoire: six cVDPV2-positive environmental samples
- DR Congo: three cVDPV1 cases and one cVDPV2 case
- Guinea: eight cVDPV2 cases and four positive environmental samples
- Niger: one cVDPV2 case and one positive environmental sample
- Nigeria: four cVDPV2 cases and two positive environmental samples
- Senegal: one cVDPV2-positive environmental sample
- Yemen: one cVDPV2 case
- Zimbabwe: one cVDPV2-positive environmental sample



#### ***Contents [click to move among sections]***

*:: Milestones, Perspectives*

*:: WHO*

*:: Organization Announcements*

*:: Journal Watch*

*:: Pre-Print Servers*



#### **WHO & Regional Offices** [to 03 Feb 2024]

<https://www.who.int/news>

*Selected News/Announcements/Statements*

2 February 2024 *Highlights*

**The updated WHO Benchmarks for Strengthening Health Emergency Capacities expanded to include public health and social measures (PHSM)**

2 February 2024 *Departmental news*

**Avian influenza and Lunar New Year festivities: vigilance and precautions**

1 February 2024 *News release*

**Global cancer burden growing, amidst mounting need for services**

31 January 2024 *Departmental news*

**WHO and MPP announce technology transfer license to enable greater patient access to multiple essential diagnostics**

31 January 2024 *News release*

[\*\*WHO introduces the Health Technology Access Pool\*\*](#)

31 January 2024 *Departmental news*

[\*\*Message by the Director of the Department of Immunization, Vaccines and Biologicals at WHO - January 2024\*\*](#)

30 January 2024 *Departmental news*

[\*\*The Technical Advisory Group on the Responsible Use of the Life Sciences and Dual-Use Research meets for the first time\*\*](#)

30 January 2024 *Statement*

[\*\*Statement by Principals of the Inter-Agency Standing Committee: We cannot abandon the people of Gaza\*\*](#)

30 January 2024 *Departmental news*

[\*\*WHO and partners call for renewed global efforts to unite, act and eliminate neglected tropical diseases\*\*](#)

.....

**WHO Regional Offices**

*Selected Press Releases, Announcements*

**WHO African Region**

:: 02 February 2024

[\*\*Zambia steps up cervical cancer screening with HPV testing\*\*](#)

:: 30 January 2024

[\*\*Sustaining the fight against neglected tropical diseases in South Sudan\*\*](#)

**WHO Region of the Americas PAHO**

:: [\*\*Global cancer burden growing, amidst mounting need for services\*\*](#)

1 February 2024, Lyon, France; Geneva, Switzerland — Ahead of World Cancer Day, the World Health Organization (WHO)'s cancer agency, the International Agency for Research on Cancer (IARC), released the latest estimates of the global burden of cancer. WHO also published survey results from 115 countries, showing a majority of...

:: [\*\*PAHO calls for renewed surveillance and increased vaccination efforts as measles cases rise globally\*\*](#)

Washington, DC, January 30, 2024 (PAHO)- The Pan American Health Organization (PAHO) published an epidemiological alert urging countries to intensify vaccination activities, epidemiological surveillance, and rapid response preparedness for possible measles outbreaks in the region, given the increase in cases worldwide and the detection of imported...

**WHO South-East Asia Region SEARO**

:: 1 February 2024 *News release*

[\*\*Ms Saima Wazed takes charge as Regional Director, WHO South-East Asia\*\*](#)

**WHO European Region EURO**

*Website not responding at inquiry.*

**WHO Eastern Mediterranean Region EMRO**



:: [WHO and France strengthen Iranian pre-hospital emergency response for Afghan refugees and deprived communities](#)

29 January 2024

**WHO Western Pacific Region**

*No new digest content identified.*

.....

**WHO - Emergency situation reports**

*No new digest content identified.*

.....

**Disease Outbreak News (DONs)**

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.*

*No new digest content identified.*

.....

**Weekly Epidemiological Record**

<https://www.who.int/publications/journals/weekly-epidemiological-record>

**Vol. 99, No. 05, pp. 49–60 2 February 2024**

<https://iris.who.int/bitstream/handle/10665/375888/WER9905-eng-fre.pdf>

:: WHO's Health Emergencies Programme: acute emergencies monthly summary – December 2023

:: Strengthening capacity for use of geographical information systems in assessment of risk and exposure to natural hazards in the Region of the Americas

.....

**New WHO Publications**

<https://www.who.int/publications/i>

*Selected*

1 February 2024

[Imagining futures of 3D bioprinting](#)

31 January 2024

[Global spending on health: Coping with the pandemic](#)

30 January 2024

[Global Consultation for updating operational plans for island countries and countries close to elimination...](#)

30 January 2024

[Application of the essential public health functions: an integrated and comprehensive approach to public...](#)

30 January 2024

[Health and Energy Platform of Action report 2020-2022: building connections for better health](#)

30 January 2024

[Multisectoral collaboration at the human-animal-environmental interface](#)

29 January 2024

[Report of the seventeenth meeting of the Strategic and technical advisory group for neglected tropical...](#)

28 January 2024

[Ending disease in Africa: control, elimination, and eradication efforts for neglected tropical diseases,...](#)

27 January 2024

[WHO Technical Advisory Group on Genomics \(TAG-G\): report of the first meeting, Geneva, Switzerland, 5-6 October 2023](#)

### *Overview*

The objective and terms of reference of the group were set out in a WHO call for interest and are available on the TAG-G website. The participants underwent a review of their individual declarations of interest before the meeting. The group includes experts with a diverse range of expertise with relevance to genomics and from across all WHO regions.

The meeting provided the opportunity for the TAG-G to meet in person for the first time, discuss current and future activities related to genomics, and provide technical advice and assistance to WHO.

.....

.....

## **USA – HHS, FDA, CDC**

### **HHS**

#### *News*

[HHS Hosts First-Ever 'Food is Medicine' Summit, Launches Three Public-Private Partnerships](#)

February 2, 2024 News Release

[Biden-Harris Administration Announces Action to Increase Access to Sickle Cell Disease Treatments](#)

January 30, 2024 News Release

### **FDA**

#### *Press Announcements*

*No new digest content identified.*

### **FDA VRBPAC**

#### *Advisory Committee Calendar*

*No new meetings scheduled.*

**CDC/ACIP [U.S.]** [to 03 Feb 2024]

<http://www.cdc.gov/media/index.html>

*Latest News Releases*

*No new digest content identified.*

## **ACIP Meetings**

*Next ACIP Meeting*

February 28-29

## **MMWR Weekly**

<https://www.cdc.gov/mmwr/index2023.html>

**February 1, 2024 / No. 4**

[PDF of this issue](#)

- [Surveillance for Acute Flaccid Myelitis — United States, 2018–2022](#)
- [Early Estimates of Updated 2023–2024 \(Monovalent XBB.1.5\) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024](#)
- [Notes from the Field: Dengue Outbreak — Peru, 2023](#)

.....

.....

## **Europe**

### **European Medicines Agency [EMA]**

<https://www.ema.europa.eu/en/news>

*News & Press Releases*

#### [Clinical trials' transition to new EU system - one year left](#)

All ongoing clinical trials in the EU must be transitioned to the Clinical Trials Information System (CTIS) by 31 January 2025.

31 January 2024

.....

### **European Centre for Disease Prevention and Control**

<https://www.ecdc.europa.eu/en>

*News/Updates/Reports/Publications [Selected]*

*No new digest content identified.*

.....

.....

### **Africa CDC [to 03 Feb 2024]**

<http://www.africacdc.org/>

*Press Releases, Statements [Selected]*

#### [Revital Healthcare, Driving African Local Manufacturing of Medical Devices](#)

2 February 2024

*Communiqué*

#### [Communiqué from Africa CDC on the Southern Africa Development Community \(SADC\) Extra Ordinary Virtual Summit of Heads of State and Government on the Cholera situation in the region](#)

2 February 2024

.....

.....

## **China CDC**

<http://www.chinacdc.cn/en/>

## **National Health Commission of the People's Republic of China** [to 03 Feb 2024]

<http://en.nhc.gov.cn/>

*News*

*No new digest content identified.*

## **National Medical Products Administration – PRC** [to 03 Feb 2024]

<http://english.nmpa.gov.cn/>

*News*

*No new digest content identified.*

## **China CDC Weekly Reports: Current Volume (6) 2024-02-02 / No. 5 COLD SPELL ISSUE**

*No new digest content identified.*

.....  
.....

### ***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....  
.....

### ***Organization Announcements***

## **Paul G. Allen Frontiers Group** [to 03 Feb 2024]

<https://alleninstitute.org/news-press/>

*News*

*No new digest content identified.*

## **BMGF - Gates Foundation** [to 03 Feb 2024]

<https://www.gatesfoundation.org/ideas/media-center>

*Press Releases and Statements*

*No new digest content identified.*

## **Bill & Melinda Gates Medical Research Institute** [to 03 Feb 2024]

<https://www.gatesmri.org/news>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*News: Articles and Publications*

*No new digest content identified.*

**CARB-X** [to 03 Feb 2024]

<https://carb-x.org/>

*News*

*No new digest content identified.*

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 03 Feb 2024]

<http://cepi.net/>

*Latest News*

*No new digest content identified.*

**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 03 Feb 2024]

<https://cioms.ch/>

*News; Publications; Events*

*No new digest content identified.*

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 03 Feb 2024]

<https://www.darpa.mil/news>

*News*

*No new digest content identified.*

**Duke Global Health Innovation Center** [to 03 Feb 2024]

<https://dukeghic.org/>

*News*

*No new digest content identified.*

**EDCTP** [to 03 Feb 2024]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*News*

30 January 2024

[\*\*World NTD Day 2024: investing to control and eliminate neglected tropical diseases\*\*](#)

**Emory Vaccine Center** [to 03 Feb 2024]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [to 03 Feb 2024]

<http://www.euvaccine.eu/>

*Latest News, Events*

*No new digest content identified.*

**Evidence Aid** [to 03 Feb 2024]

*Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.*

<http://www.evidenceaid.org/>

*Resources [Selected]*

**[Health in populations displaced forcibly after disasters](#)**

Added February 1, 2024

**[Adherence to medicines among immigrants and refugees](#)**

Added January 30, 2024

**Fondation Merieux** [to 03 Feb 2024]

<http://www.fondation-merieux.org/>

*News, Events*

*No new digest content identified.*

**Gavi** [to 03 Feb 2024]

<https://www.gavi.org/>

*News Releases*

*No new digest content identified.*

**GE2P2 Global Foundation** [to 03 Feb 2024]

[www.ge2p2.org](http://www.ge2p2.org)

*News/Analysis/Publications-Digests/Statements*

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – February 2024](#)

:: [Genomic Medicine – Governance, Ethics, Policy, Practice: A Monthly Digest](#) – Oct 2023

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 09 January 2024 – Issue 12](#)

**GHIT Fund** [to 03 Feb 2024]

<https://www.ghitfund.org/newsroom/press>

*Press Releases*

*No new digest content identified.*

**Global Fund** [to 03 Feb 2024].

<https://www.theglobalfund.org/en/news/>

*News & Stories*

*No new digest content identified.*

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 03 Feb 2024]

<https://www.glopid-r.org/news/>

*News*

*No new digest content identified.*

**Hilleman Laboratories** [to 03 Feb 2024]

<http://www.hilleman-labs.org/>

*News & Insights*

*No new digest content identified.*

**HHMI - Howard Hughes Medical Institute** [to 03 Feb 2024]

<https://www.hhmi.org/news>

*Press Room*

*No new digest content identified.*

**Human Immunome Project [nee Human Vaccines Project]** [to 03 Feb 2024]

<http://www.humanvaccinesproject.org/>

*News*

*No new digest content identified.*

**IAVI** [to 03 Feb 2024]

<https://www.iavi.org/>

*News, Features*

**[Penta – Child Health Research announces new partnership with IAVI and Achilles Vaccines](#)**

February 1, 2024

Partnership will advance monoclonal antibody development.

**INSERM** [to 03 Feb 2024]

<https://www.inserm.fr/en/home/>

*Press Releases*

*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

**ICH - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use** [to 03 Feb 2024]

<https://www.ich.org/page/press-releases>

*News/Pubs/Press Releases [Selective]*

*No new digest content identified.*

**ICRC** [to 03 Feb 2024]

<https://www.icrc.org/en/whats-new>

*What's New [Selected]*  
*No new digest content identified.*

**IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*

*No new digest content identified.*

**IFRC** [to 03 Feb 2024]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Press Releases [Selected]*

**[IFRC Global COVID-19 study: vaccine bank an 'essential element' of next pandemic response](#)**

31/01/2024 | Press release

**Institut Pasteur** [to 03 Feb 2024]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*No new digest content identified.*

**ISC / International Science Council** [to 03 Feb 2024]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*Latest Updates*

*Blogs*

**[A promising year ahead for scientific publishing](#)**

2023 emerged as a landmark year for scientific publishing, characterized by widespread calls for reform from researchers, journal editors, funding agencies, government and non-governmental entities alike. As we reflect on the year, there are more voices within the academic community speaking to the need of the existing publishing and research evaluation systems to change.

by 7 March.

29.01.2024

**International Union of Immunological Societies (IUIS)**

<https://iuis.org/>

*News/Events [Selected]*

*No new digest content identified.*

**IVAC** [to 03 Feb 2024]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

*No new digest content identified.*



**IVI** [to 03 Feb 2024]

<http://www.ivi.int/>

*IVI News & Announcements*

*No new digest content identified.*

**Johns Hopkins Center for Health Security** [to 03 Feb 2024]

<https://centerforhealthsecurity.org/newsroom>

*Center News [Selected]*

*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 03 Feb 2024]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*South Sudan*

**[MSF launches mass vaccination campaign amid deadly hepatitis E outbreak in South Sudan](#)**

Press Release 30 Jan 2024

*Gaza-Israel war*

**[Displaced pregnant women at high risk amid dire conditions in Rafah](#)**

Project Update 29 Jan 2024

**National Academy of Medicine** - USA [to 03 Feb 2024]

<https://nam.edu/programs/>

*News [Selected]*

*No new digest content identified.*

**National Academy of Sciences** - USA [to 03 Feb 2024]

<https://www.nationalacademies.org/newsroom?>

*News*

**[New Voices Program for Emerging STEM Leaders Announces New Members](#)**

*News Release | February 1, 2024*

WASHINGTON — The National Academies of Sciences, Engineering, and Medicine's [New Voices in Sciences, Engineering, and Medicine](#) program has announced its [2024 cohort of members](#), a group of 26 outstanding early- and mid-career scientists, engineers, and medical professionals.

**National Vaccine Program Office** - U.S. HHS [to 03 Feb 2024]

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

February 22-23, 2024 (Virtual)

**NIH** [to 03 Feb 2024]

<http://www.nih.gov/>

*News Releases*

*No new digest content identified.*

**PATH** [to 03 Feb 2024]

<https://www.path.org/media-center/>

*Newsroom*

*No new digest content identified.*

**Rockefeller Foundation** [to 03 Feb 2024]

<https://www.rockefellerfoundation.org/>

*Press Releases and Speeches*

Jan 31 2024 Press Releases

**[U.S. Department of Health and Human Services and The Rockefeller Foundation Partner To Accelerate the Adoption of Food Is Medicine in Health Systems](#)**

Jan 29 2024 Press Releases

**[IIT Delhi and The Rockefeller Foundation To Establish the Chair for Climate Sciences and Technology](#)**

**Sabin Vaccine Institute** [to 03 Feb 2024]

<https://www.sabin.org/press/>

*Latest News & Press Releases*

*No new digest content identified.*

**UNAIDS** [to 03 Feb 2024]

<http://www.unaids.org/en>

*Selected Press Releases/Reports/Statements*

*Press statement*

**[UNAIDS Executive Director: let women and girls lead to protect and advance human rights globally](#)**

OSLO/GENEVA, 1 February 2024

**UNICEF** [to 03 Feb 2024]

<https://www.unicef.org/media/press-releases>

*Latest press releases, news notes and statements*

*Remarks* 02 February 2024

**[Stories of loss and grief: At least 17,000 children are estimated to be unaccompanied or separated from their parents in the Gaza Strip](#)**

<https://www.unicef.org/press-releases/stories-loss-and-grief-least-17000-children-are-estimated-be-unaccompanied-or>

GENEVA, 2 February 2023 – "UNICEF estimates that at least 17,000 children in the Gaza Strip are unaccompanied or separated. Each one, a heartbreaking story of loss and grief. "This corresponds to 1% of the overall displaced population - 1.7 million people. "Of course, this is an estimation since it is nearly impossible to gather and verify...

*Statement* 31 January 2024

**[Statement by Principals of the Inter-Agency Standing Committee: We cannot abandon the people of Gaza](#)**

<https://www.unicef.org/press-releases/statement-principals-inter-agency-standing-committee-we-cannot-abandon-people-gaza>

NEW YORK/GENEVA/ROME, 30 January 2024 – The allegations of involvement of several UNRWA staff in the heinous attacks on Israel on 7 October are horrifying. As the Secretary-General has said, any UN employee involved in acts of terror will be held accountable. However, we must not prevent an entire organization from delivering on its mandate to...

*Press release* 30 January 2024

**[At least 170,000 children displaced amid escalating violence in Haiti](https://www.unicef.org/press-releases/least-170000-children-displaced-amid-escalating-violence-haiti)**

<https://www.unicef.org/press-releases/least-170000-children-displaced-amid-escalating-violence-haiti>

PORT-AU-PRINCE/NEW YORK, January 29, 2024 –The surge in armed violence across Haiti has triggered a profound humanitarian crisis, with the number of internally displaced children soaring to 170,000. This alarming figure represents a twofold increase from last year, highlighting the rapidly deteriorating situation and its deep impact on the coun

**Unitaid** [to 03 Feb 2024]

<https://unitaid.org/>

*Featured News*

02 February 2024

**[Need to improve oxygen access has not ended with the pandemic](#)**

**Vaccine Equity Cooperative [nee Initiative]** [to 03 Feb 2024]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative (Sabin)** [to 03 Feb 2024]

<https://www.vaccineacceptance.org/>

*Announcements, Blog*

*Vaccination Acceptance Research Network*

**[VARN2023 Conference Report](#)**

January 31, 2024

The VARN2023 Conference Report summarizes the key findings from the 2023 Vaccine Acceptance Research Network (VARN) Conference held in Bangkok, Thailand, June 13-15, 2023. Highlighting the latest research and current policy and programmatic challenges, opportunities, and strategies related to vaccine acceptance, demand, and delivery, this report is the result of the first in-person convening of the VARN that was attended by 231 researchers and professionals across 47 countries. This is a useful resource for public health professionals, researchers, and policymakers working in immunization across contexts and settings.

**Vaccine Confidence Project** [to 03 Feb 2024]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 03 Feb 2024]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

*No new digest content identified.*

**Wellcome Trust** [to 03 Feb 2024]

<https://wellcome.org/>

*News, Opinion, Reports*

*No new digest content identified.*

**The Wistar Institute** [to 03 Feb 2024]

<https://www.wistar.org/news/press-releases>

*Press Releases*

February 1, 2024

**[PCOM, The Wistar Institute Announce Innovative Biomedical Sciences Collaboration](#)**

In a move designed to advance opportunities for students to expand their access to cutting-edge research and education in the field of biomedical sciences, Philadelphia College of Osteopathic Medic...

**World Bank** [to 015 Oct 2022]

<http://www.worldbank.org/en/news/all>

*All News [Selected]*

*No new digest content identified.*

**WFPHA: World Federation of Public Health Associations** [to 03 Feb 2024]

<https://www.wfpha.org/>

*Blog*

*No new digest content identified.*

**[World Medical Association \[WMA\]](#)** [to 03 Feb 2024]

<https://www.wma.net/news-press/press-releases/>

*Press Releases*

**[Declaration of Helsinki – Phase I Public Comment Period](#)**

In order to maximize input by all stakeholders and the public, we are providing two separate public comment periods. A phase 1 public comment period is being held now to address issues from the first few regional meetings, and a phase 2 comment period will follow in the spring when additional topics have been addressed.

*Open Now: Phase 1 Public Comment Period Due: 7 February 2024.*

The workgroup's proposed edits to date are now available for public comment. To submit your or your organization's feedback, download the [phase 1 public comment document](#)

**World Organisation for Animal Health** [to 03 Feb 2024]

<https://www.oie.int/en/>

*Press Releases, Statements*

*No new digest content identified.*

.....

**ARM [Alliance for Regenerative Medicine]** [to 03 Feb 2024]

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

**[ARM welcomes the release of the Center for Medicare and Medicaid Innovation's \(CMMI\) Cell and Gene Therapy Access Model](#)**

January 31, 2024

Washington, DC

The voluntary model recognizes that transformative, durable, and potentially curative gene therapies require innovative thinking about access, payment, and healthcare delivery.

**BIO** [to 03 Feb 2024]

<https://www.bio.org/press-releases>

*Press Releases*

*No new digest content identified.*

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 03 Feb 2024]

<http://www.dcvmn.org/>

*News; Upcoming events*

*No new digest content identified.*

**ICBA – International Council of Biotechnology Associations** [to 03 Feb 2024]

<https://internationalbiotech.org/news/>

*News*

*No new digest content identified.*

**IFPMA** [to 03 Feb 2024]

<https://ifpma.org/>

*Selected Press Releases/Statements*

*No new digest announcements identified.*

**International Alliance of Patients' Organizations – IAPO** [to 03 Feb 2024]

<https://www.iapo.org.uk/news>

*Press and media [Selected]*

**[IAPO's Transition of Leadership and Strategic Direction for 2024 and Beyond](#)**

Monday, 29 January 2024

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

*No new digest announcements identified.*

**PhRMA** [to 03 Feb 2024]

<http://www.phrma.org/>

*Press Releases*

*No new digest announcements identified.*



## ***Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements***

### **AstraZeneca**

*Press Releases* - No new digest announcements identified.

### **Bharat Biotech**

*Press Releases* - No new digest announcements identified.

### **BioCubaFarma – Cuba**

*Últimas Noticias* - No new digest announcements identified

### **Biological E**

*News* - No new digest announcements identified

### **BioNTech**

*Press Releases*

31 January 2024

[\*\*BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305\*\*](#)

### **Boehringer**

*Press Releases* - No new digest announcements identified.

### **CanSinoBIO**

*News* - Website not responding at inquiry

### **CIGB**

*Latest News* - No new digest announcements identified.

### **Cinnagen**

*Recent News* - No new digest announcements identified.

### **Clover Biopharmaceuticals - China**

*News* - No new digest announcements identified.

### **Curevac [Bayer Ag – Germany]**

*News* - No new digest announcements identified

### **Gamaleya National Center/Sputnik**

*Latest News and Events* - No new digest announcements identified

<https://sputnikvaccine.com/> - No new digest announcements identified

### **GSK**

*Press releases for media*

29 January 2024

[\*\*GSK's RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency for the prevention of RSV disease in adults aged 50-59 at increased risk\*\*](#)

Application supported by positive results of a Phase III study showing immune response and acceptable tolerability profile.

## **IMBCAMS, China**

Home - Website not responding at inquiry.

## **Janssen/JNJ**

Press Releases - No new digest announcements identified

## **Merck**

News releases - No new digest announcements identified

## **Moderna**

Press Releases - No new digest announcements identified

## **Nanogen**

News - No new digest announcements identified

## **Novartis**

News - No new digest announcements identified.

## **Novavax**

Press Releases

Feb 2, 2024 Statement

Malaria

### **[R21/Matrix-M™ Malaria Vaccine Phase 3 Trial Results Published in The Lancet](#)**

Today, peer-reviewed results from a Phase 3 efficacy trial of the R21/Matrix-M™ malaria vaccine were published in *The Lancet*. The trial was conducted across multiple sites in four African countries with 4,800 children aged 5-36 months...

Jan 31, 2024 Statement

Corporate and finance

### **[Novavax Continues Transformation of Company Focused on Product Delivery, Financial Performance and Expanded Portfolio](#)**

## **Pfizer**

Recent Press Releases - No new digest announcements identified.

## **R-Pharm**

<https://rpharm-us.com/index.php>

[No news or media page identified]

## **Sanofi Pasteur**

Press Releases

February 1, 2024

### **[François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee](#)**

## **Serum Institute of India**

NEWS & ANNOUNCEMENTS

Thursday, February 01, 2024

### **[New Phase 3 Trial Data Confirm the Uniquely High Efficacy and Good Safety Profile of the R21/Matrix-M™ Malaria Vaccine in African Children ...](#)**

## **Sinopharm/WIBPBIBP**

*[News](#) - No new digest announcements identified [English translation function not operating]*

## **Sinovac**

*[Press Releases](#) - No new digest announcements identified*

## **SK Biosciences**

*[Press Releases](#) - No new digest announcements identified.*

## **Takeda**

*[Newsroom](#)*

### **[Takeda Announces Chief Financial Officer Succession](#)**

February 1, 2024

## **Valneva**

*[Press Releases](#) - No new digest announcements identified.*

## **Vector State Research Centre of Virology and Biotechnology**

*[Home](#) - Website not responding [404 error]*

## **WestVac Biopharma**

*[Media](#)*

### **[WestVac Biopharma Obtains PIC/S GMP Certification from Mexico](#)**

2024-01-24

Recently, WestVac Biopharma received the GMP (Good Manufacturing Practice) certificate from the Federal Commission for Protection against Health Risks (COFEPRIS) in Mexico, a member of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S). This certification covers all the COVID-19 vaccines produced by WestVac Biopharma using insect cells (Sf9), including the Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) and other COVID-19 vaccine series.

## **Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

*[Website](#) [No News/Announcements page identified]*

.....  
.....

### ***[Contents](#) [click to move among sections]***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

*:: [Pre-Print Servers](#)*

.....  
.....

## ***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively



provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **AJOB Empirical Bioethics**

Volume 15, 2023 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

### **AMA Journal of Ethics**

Volume 26, Number 1: E1-96 Jan 2024

<https://journalofethics.ama-assn.org/issue/critical-pedagogies-health-professions-education>

#### ***Critical Pedagogies in Health Professions Education***

Health professions training is mainly competency driven, with students' and trainees' learning and technical skill development regularly assessed, usually in terms of standardized outcomes. Yet, there are good ethical and clinical questions to ask about competency-based medical education, specifically about how schools' and academic health centers' curricula meaningfully motivate learning and skill development about social privilege, health equity, and structural determinants of patients' health and health outcomes. This theme issue considers whether and to what extent skill development about, for example, the affective features of, say, coming to terms with one's privilege is teachable and assessable in competency-based frameworks, especially when those frameworks have a history of excluding key perspectives. Critical pedagogies investigated herein suggest strategies for interrogating teaching and learning methods and curricular content that are socially, culturally, politically, and historically fraught.

### **American Journal of Human Genetics**

Jan 04, 2024 Volume 111 Issue 1 p1-210

<https://www.cell.com/ajhg/current>

#### **This Month in The Journal**

Alyson B. Barnes, Kylee L. Spencer, Sara B. Cullinan

Biobanks are becoming increasingly common, and although each has its own goals, strengths, and challenges, the standard recipe is a focus on scientific discovery through genetic data linked to electronic health records (EHRs). In this issue, Wiley et al. describe the development of the Colorado Center for Personalized Medicine Biobank (CCPM Biobank), which is not only designed to advance research but also to directly impact patient care. A few key elements were crucial to achieving these dual aims.

[Reviewed earlier]

### **American Journal of Infection Control**

January 2024 Volume 52 Issue 1 p1-140

<http://www.ajicjournal.org/current>

[Reviewed earlier]

### **American Journal of Preventive Medicine**

January 2024 Volume 66 Issue 1 p1-194

<https://www.ajpmonline.org/current>

[Reviewed earlier]

### **American Journal of Public Health**

January 2024 114(1)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

### **American Journal of Tropical Medicine and Hygiene**

Volume 110 (2024): Issue 1 (Jan 2024)

<https://www.ajtmh.org/view/journals/tpmd/110/1/tpmd.110.issue-1.xml>

[Reviewed earlier]

### **Annals of Internal Medicine**

January 2024 Volume 177, Issue 1

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

### **Artificial Intelligence – An International Journal**

Volume 327 February 2024

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/327/suppl/C>

[Reviewed earlier]

### **BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 03 Feb 2024)

[No new digest content identified]

### **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 03 Feb 2024)

[No new digest content identified]

### **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 03 Feb 2024)

#### **[Bivalent mRNA vaccine effectiveness against COVID-19 among older adults in Japan: a test-negative study from the VENUS study](#)**

*Bivalent COVID-19 vaccines have been implemented worldwide since the booster vaccination campaigns of autumn of 2022, but little is known about their effectiveness. Thus, this study holistically evaluated the ...*

Authors: Yudai Tamada, Kenji Takeuchi, Taro Kusama, Megumi Maeda, Fumiko Murata, Ken Osaka and Haruhisa Fukuda

Citation: BMC Infectious Diseases 2024 24:135

Content type: Research Published on: 29 January 2024

### **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 03 Feb 2024)

[No new digest content identified]

### **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 03 Feb 2024)

[No new digest content identified]

### **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 03 Feb 2024)

[No new digest content identified]

### **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 03 Feb 2024)

[No new digest content identified]

### **BMC Research Notes**

<http://www.biomedcentral.com/bmcresearchnotes/content>

(Accessed 03 Feb 2024)

[No new digest content identified]

### **BMJ Evidence-Based Medicine**

February 2024 - Volume 29 - 1

<https://ebm.bmj.com/content/29/1>

[Reviewed earlier]

### **BMJ Global Health**

January 2024 - Volume 9 - 1

<https://gh.bmj.com/content/9/1>

[Reviewed earlier]

### **Bulletin of the Atomic Scientists**

January 2024

<https://thebulletin.org/magazine/2024-01/>

[Reviewed earlier]

### **Bulletin of the World Health Organization**

Volume 102(2); 2024 Feb 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/454958/>

*Editorials*

**[Global health inequities: more challenges, some solutions](#)**

Viroj Tangcharoensathien, Angkana Lekagul, Yik-Ying Teo

Bull World Health Organ. 2024 Feb 1; 102(2): 86–86A. Published online 2024 Feb 1.

doi: 10.2471/BLT.24.291326

PMCID: PMC10835631

*Research*

**[Health policy implications of corporate social responsibility provisions in international investment agreements](#)**

Takwa Tissaoui, Teresa Davis, Helen Trevena, Anne Marie Thow

Bull World Health Organ. 2024 Feb 1; 102(2): 94–104D. Published online 2023 Dec 8.

doi: 10.2471/BLT.23.290419

PMCID: PMC10835630

*Policy & Practice*

**[Health workforce data needed to minimize inequities associated with health-worker migration](#)**

Margaret Walton-Roberts, Ivy L Bourgeault

Bull World Health Organ. 2024 Feb 1; 102(2): 117–122. Published online 2023 Nov 21.

doi: 10.2471/BLT.23.290028

PMCID: PMC10835628

**[Forum shifting in global health security](#)**

Clare Wenham

Bull World Health Organ. 2024 Feb 1; 102(2): 123–129. Published online 2023 Oct 31.

doi: 10.2471/BLT.23.290480

PMCID: PMC10835629

**[Developing an agenda for the decolonization of global health](#)**

David McCoy, Anuj Kapilashrami, Ramya Kumar, Emma Rhule, Rajat Khosla

Bull World Health Organ. 2024 Feb 1; 102(2): 130–136. Published online 2023 Dec 8.

doi: 10.2471/BLT.23.289949

PMCID: PMC10835633

*Perspectives*

**[Evaluating global health initiatives to improve health equity](#)**

Shams El Arifeen, John Grove, Peter M Hansen, James R Hargreaves, Hope L Johnson, Mira Johri, Esther Saville

Bull World Health Organ. 2024 Feb 1; 102(2): 137–139. Published online 2023 Oct 31.

doi: 10.2471/BLT.23.290531

PMCID: PMC10835640

**[Tracking migration and health inequities](#)**

Elisa Mosler Vidal, Kolitha Prabash Wickramage

Bull World Health Organ. 2024 Feb 1; 102(2): 143–145. Published online 2023 Dec 14.

doi: 10.2471/BLT.23.290776

PMCID: PMC10835634

**[Research needed on urban Indigenous health inequalities](#)**

Abdullah A Mamun, Edmund Wedam Kanmiki, Stuart Leske, Janet Stajic, James Ward

Bull World Health Organ. 2024 Feb 1; 102(2): 146–148. Published online 2023 Dec 29.  
doi: 10.2471/BLT.23.290868  
PMCID: PMC10835635

## Cell

Feb 01, 2024 Volume 187 Issue 3 p511-796

<https://www.cell.com/cell/current>

[New issue; No digest content identified]

## Child Care, Health and Development

Volume 50, Issue 1 January 2024

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

## Clinical Pharmacology & Therapeutics

Feb 01, 2024 Volume 187 Issue 3 p511-796

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

*Editorial*

### [Progress in Clinical Pharmacology in China: A Randomized Controlled Study to Advance Genotype-Guided Precision Medicine](#)

Liang Zhao, Kathleen M. Giacomini, Piet H. van der Graaf

Pages: 169-172

First Published: 22 January 2024

## Clinical Therapeutics

January 2024 Volume 46 Issue 1 p1-84

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

## Clinical Trials

Volume 20 Issue 6, December 2023

<https://journals.sagepub.com/toc/ctja/20/6>

[Reviewed earlier]

## Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 03 Feb 2024]

### [Not only vaccine hesitancy, but also vaccination campaign hesitancy drives measles epidemics in conflict-torn eastern DR Congo](#)

*The COVID-19 pandemic and vaccine hesitancy are not the only causes of the increase in measles cases in low- and middle-income countries. Measles epidemics, like the recent one in eastern DRC, are often quickly halted by mass vaccination in 'easy to reach' refugee camps. However, governmental and humanitarian actors fail to respond effectively in 'hard-to-reach' areas like Masisi, frequently limiting themselves to more accessible areas close to big cities.*

Authors: Daan Van Brusselen, Ali Heshima Dubois, Lucien Kandundao Bindu, Zakari Moluh, Yvonne Nzomukunda and Laurens Liesenborghs

Citation: Conflict and Health 2024 18:14  
Content type: Comment Published on: 1 February 2024

**[Impact of Ebola and COVID-19 on maternal, neonatal, and child health care among populations affected by conflicts: a scoping review exploring demand and supply-side barriers and solutions](#)**

*Armed conflicts have a severe impact on the health of women and children. Global health emergencies such as pandemics and disease outbreaks further exacerbate the challenges faced by vulnerable populations in accessing maternal, neonatal, and child healthcare (MNCH). There is a lack of evidence that summarizes the challenges faced by conflict-affected pregnant women, mothers, and children in accessing MNCH services during global health emergencies, mainly the Ebola and COVID-19 pandemics. This scoping review aimed to analyze studies evaluating and addressing barriers to accessing comprehensive MNCH services during Ebola and COVID-19 emergencies in populations affected by conflict.*

Authors: Yasir Shafiq, Elena Rubini, Zoha Zahid Fazal, Muhammad Murtaza Bukhari, Maheen Zakaria, Noor ul Huda Zeeshan, Ameer Muhammad, Luca Ragazzoni, Francesco Barone-Adesi and Martina Valente

Citation: Conflict and Health 2024 18:12  
Content type: Review Published on: 30 January 2024

**Contemporary Clinical Trials**

Volume 135 December 2023

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/135/suppl/C>

[Reviewed earlier]

**The CRISPR Journal**

Volume 6, Issue 6 / December 2023

<https://www.liebertpub.com/toc/crispr/6/6>

[Reviewed earlier]

**Current Genetic Medicine Reports**

Volume 11, issue 1-2, June 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-1>

[Reviewed earlier]

**Current Medical Research and Opinion**

Volume 40, Issue 1 2024

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

**Current Opinion in Infectious Diseases**

February 2024 - Volume 37 - Issue 1

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

**Current Protocols in Human Genetics**

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 03 Feb 2024]

[No new digest content identified]

### **Developing World Bioethics**

Volume 23, Issue 4 Pages: 293-377 December 2023

<https://onlinelibrary.wiley.com/toc/14718847/current>

*ORIGINAL ARTICLES*

[Reviewed earlier]

### **Development in Practice**

Volume 33, Issue 8, 2023

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

### **Development Policy Review**

Volume 42, Issue 1 January 2024

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

### **Disaster Medicine and Public Health Preparedness**

Volume 17 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

### **Disasters**

Volume 47, Issue 4 Pages: 847-1173 October 2023

<https://onlinelibrary.wiley.com/toc/14677717/2023/47/4>

[Reviewed earlier]

### **EMBO Reports**

Volume 25 Issue 1 12 January 2024

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

### **Emerging Infectious Diseases**

Volume 29, Number 12—December 2023

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

### **Epidemics**

Volume 45 December 2023

<https://www.sciencedirect.com/journal/epidemics/vol/45/suppl/C>

[Reviewed earlier]

### **Epidemiology and Infection**

Volume 152 - 2024

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

### **Ethics & Human Research**

Volume 46, Issue 1 Pages: 1-48 January–February 2024

<https://onlinelibrary.wiley.com/toc/25782363/current>

• *Local context and emergency research* • *Participant fraud in online research*  
*Passing demands in autism research :: Women missing in phase I trials*

[Reviewed earlier]

### **Ethics & International Affairs**

Volume 37 - Issue 4 - Winter 2023

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

### **Ethics, Medicine and Public Health**

Volume 31 (December 2023)

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C>

[Reviewed earlier]

### **The European Journal of Public Health**

Volume 33, Issue 6, December 2023

<https://academic.oup.com/eurpub/issue/33/6>

[Reviewed earlier]

### **Expert Review of Vaccines**

Vol 23 (1) 2023

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

### **Foreign Affairs**

January/February 2024 Volume 103, Number 1

<https://www.foreignaffairs.com/issues/2023/103/1>

[Reviewed earlier]

### **Forum for Development Studies**

Volume 50, 2023 - Issue 3

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]



## **Genetics in Medicines**

Volume 26, Issue 1 January 2024

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/2>

[Reviewed earlier]

## **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 03 Feb 2024]

[No new digest content identified]

## **Global Health Action**

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/zgha20/current?nav=toCList>

[Reviewed earlier]

## **Global Health: Science and Practice (GHSP)**

Vol. 11, No. 6 December 22, 2023

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

## **Global Legal Monitor & Legal Reports – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>

[https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date\\_desc](https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc)

[Accessed 03 Feb 2024]

[No new digest content identified]

## **Global Public Health**

Volume 19, Issue 1 (2024)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

## **Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 03 Feb 2024]

### **[Developing a protocol on antimicrobial resistance through WHO's pandemic treaty will protect lives in future pandemics](#)**

*Addressing antimicrobial resistance (AMR) through the pandemic treaty is a crucial aspect of pandemic prevention, preparedness, and response. At the moment, AMR-related provisions in the draft text do not go far enough and will likely lead countries to commit to the status-quo of AMR action. We suggest that the protocol mechanism of the treaty proposed under Article 31 offers an opportunity to develop a subsidiary agreement (or protocol) to further codify the specific obligations and enforcement mechanisms necessary to meet the treaty's AMR provisions. We also highlight experiences with previous treaty implementation that relied on protocols to inform design of a future AMR protocol.*

Authors: Arne Ruckert, Shajoe Lake and Susan Rogers Van Katwyk

Citation: Globalization and Health 2024 20:10

Content type: Commentary Published on: 31 January 2024

### **Health and Human Rights**

Volume 25, Issue 2, December 2023

<https://www.hhrjournal.org/volume-25-issue-2-december-2023/>

***Special Section: Economic Inequality and the Right to Health***

[Reviewed earlier]

### **Health Economics, Policy and Law**

Volume 18 - Special Issue 4 - October 2023

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

***SPECIAL ISSUE: On the roof top of health policy change***

[Reviewed earlier]

### **Health Policy and Planning**

Volume 38, Issue 10, December 2023

<https://academic.oup.com/heapol/issue/38/10>

[Reviewed earlier]

### **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

*Research*

**[The use of implementation science theories, models, and frameworks in implementation research for medicinal products: A scoping review](#)**

*The uptake, adoption and integration of new medicines and treatment regimens within healthcare delivery can take a decade or more. Increasingly, implementation science (IS) research is being used to bridge this gap between the availability of new therapeutic evidence and its actual application in clinical practice. Little is known, however, about the quality of IS research in this area, including the degree to which theories, models and frameworks (TMFs) are being used. The objective of this study was to conduct a scoping review of the use of TMFs in implementation research involving medicinal products.*

Authors: Meredith Y. Smith, Bridget Gaglio and Milena Anatchkova

Citation: Health Research Policy and Systems 2024 22:17

Content type: Research Published on: 29 January 2024

### **Human Gene Therapy**

Volume 35, Issue 1-2 / January 2024

<https://www.liebertpub.com/toc/hum/35/1-2>

[Reviewed earlier]

### **Humanitarian Practice Network**

<https://odihpn.org/>

*Featured Publications*

[No new digest content identified]

## **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 19, Issue 3, 2023

<https://www.tandfonline.com/toc/khvi20/19/3?nav=tocList>

[Reviewed earlier]

## **Immunity**

Jan 09, 2024 Volume 57 Issue 1 p1-192

<https://www.cell.com/immunity/current>

[Reviewed earlier]

## **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>

[Accessed 03 Feb 2024]

[No new digest content identified]

## **Infectious Diseases of Poverty**

<http://www.idpjournal.com/content>

[Accessed 03 Feb 2024]

### **[Promoting higher-valent pediatric combination vaccines in China: challenges and recommendations for action](#)**

*Many countries have adopted higher-valent pediatric combination vaccines to simplify vaccination schedules and minimize health expenditures and social costs. However, China is conservative in the use of pediat...*

Authors: Jiuling Li, Shu Chen, Edwin Asturias, Shenglan Tang and Fuqiang Cui

Citation: Infectious Diseases of Poverty 2024 13:12

Content type: Commentary Published on: 1 February 2024

## **International Health**

Volume 15, Issue 6, November 2023

<https://academic.oup.com/inthealth/issue/15/6>

[Reviewed earlier]

## **International Human Rights Law Review**

Volume 12 (2023): Issue 2 (Dec 2023)

<https://brill.com/view/journals/hrlr/12/2/hrlr.12.issue-1.xml>

*Table of Contents*

[Reviewed earlier]

## **International Journal of Community Medicine and Public Health**

Vol. 11 No. 1 (2024): January 2024

<https://www.ijcmph.com/index.php/ijcmph/issue/view/108>

[Reviewed earlier]

### **International Journal of Epidemiology**

Volume 52, Issue 6, December 2023

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

### **International Journal of Human Rights in Healthcare**

Volume 16 Issue 5 2023

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/16/iss/3>

*Table of contents*

[New issue; No digest content identified]

### **JAMA**

January 23/30, 2024, Vol 331, No. 4, Pages 271-368

<https://jamanetwork.com/journals/jama/currentissue>

[Reviewed earlier]

### **JAMA Health Forum**

January 2024, Vol 5, No. 1

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

### **JAMA Pediatrics**

January 2024, Vol 5, No. 1

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

### **JBI Evidence Synthesis**

January 2024 - Volume 22 - Issue 1

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

### **Journal of Adolescent Health**

January 2024 Volume 74 Issue 1 p1-212

<https://www.jahonline.org/current>

[Reviewed earlier]

### **Journal of Artificial Intelligence Research**

Vol. 78 (2023)

<https://www.jair.org/index.php/jair>

*Contents*

[Reviewed earlier]

### **Journal of Community Health**

Volume 48, issue 6, December 2023

<https://link.springer.com/journal/10900/volumes-and-issues/48-6>

[Reviewed earlier]

**Journal of Current Medical Research and Opinion**

*...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.*

Vol. 7 No. 01 (2024), January 2, 2024 , Page 1988-1996

<https://www.cmro.in/index.php/jcmro/issue/view/75>

[New issue; No digest content identified]

**Journal of Development Economics**

Volume 166 January 2024

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/166/suppl/C>

[Reviewed earlier]

**Journal of Empirical Research on Human Research Ethics**

Volume 18 Issue 5, December 2023

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

**Journal of Epidemiology & Community Health**

February 2024 - Volume 78 - 2

<https://jech.bmj.com/content/78/2>

[New issue; No digest content identified]

**Journal of Evidence-Based Medicine**

Volume 16, Issue 4 Pages: 415-580 December 2023

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

**Journal of Global Ethics**

Volume 19, Issue 3 (2023)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 34, Number 4, November 2023

<https://muse.jhu.edu/issue/51329>

*Table of Contents*

[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 25, issue 6, December 2023

<https://link.springer.com/journal/10903/volumes-and-issues/25-6>

[Reviewed earlier]

### **Journal of Immigrant & Refugee Studies**

Volume 21, 2023 \_ Issue 4

<https://www.tandfonline.com/toc/wimm20/current>

***Towards a New Migration and Asylum Research Agenda for the Americas***

### **Journal of Infectious Diseases**

Volume 228, Issue 12, 15 December 2023

<https://academic.oup.com/jid/issue/228/12>

[Reviewed earlier]

### **Journal of International Development**

Volume 36, Issue 1 Pages: 1-772 January 2024

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

### **Journal of Medical Ethics**

February 2024 - Volume 50 - 2

<http://jme.bmj.com/content/current>

*Editorial*

**[Generative AI and medical ethics: the state of play](#)** (23 January, 2024) Free

Hazem Zohny, Sebastian Porsdam Mann, Brian D Earp, John McMillan

*Extended essay*

**[COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities](#)** (5 December, 2022)

Kevin Bardosh, Allison Krug, Euzebiusz Jamrozik, Trudo Lemmens, Salmaan Keshavjee, Vinay Prasad, Marty A Makary, Stefan Baral, Tracy Beth Høeg

### **Journal of Patient-Centered Research and Reviews**

Volume 10, Issue 4 (2023)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

### **The Journal of Pediatrics**

Volume 264 January 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/264/suppl/C>

[Reviewed earlier]

### **Journal of Pharmaceutical Policy and Practice**

Volume 17, Issue 1 (2024) Issue 1

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

### **Journal of Public Health Management & Practice**

January/February 2024 - Volume 30 - Issue 1

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

### **Journal of Public Health Policy**

Volume 44, issue 4, December 2023

<https://link.springer.com/journal/41271/volumes-and-issues/44-4>

[Reviewed earlier]

### **Journal of the Royal Society – Interface**

January 2024 Volume 21 Issue 210

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

### **Journal of Travel Medicine**

Volume 30, Issue 8, December 2023

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

### **Journal of Virology**

Volume 97 • Number 12 • December 2023

<http://jvi.asm.org/content/current>

[Reviewed earlier]

### **The Lancet**

Feb 03, 2024 Volume 403 Number 10425 p409-502, e7-e8

<https://www.thelancet.com/journals/lancet/issue/current>

*Editorial*

[\*\*Cancer research equity: innovations for the many, not the few\*\*](#)

The Lancet

*Articles*

[\*\*Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children\*\*](#)

Priyanka D Patel, et al. on behalf of the TyVAC team

*Seminar*

[\*\*HIV epidemiology, prevention, treatment, and implementation strategies for public health\*\*](#)

Aaloke Mody, et al.

*Online First* February 1, 2024

*Comment*

[\*\*Malaria vaccines for children: and now there are two\*\*](#)

Vasee Moorthy, Mary J Hamel, Peter G Smith

### *Articles*

#### **[Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial](#)**

Mehreen S Dattoo, et al. the R21/Matrix-M Phase 3 Trial Group

#### *Summary*

#### *Background*

Recently, we found that a new malaria vaccine, R21/Matrix-M, had over 75% efficacy against clinical malaria with seasonal administration in a phase 2b trial in Burkina Faso. Here, we report on safety and efficacy of the vaccine in a phase 3 trial enrolling over 4800 children across four countries followed for up to 18 months at seasonal sites and 12 months at standard sites...

#### *Interpretation*

R21/Matrix-M was well tolerated and offered high efficacy against clinical malaria in African children. This low-cost, high-efficacy vaccine is already licensed by several African countries, and recently received a WHO policy recommendation and prequalification, offering large-scale supply to help reduce the great burden of malaria in sub-Saharan Africa.

#### *Funding*

The Serum Institute of India, the Wellcome Trust, the UK National Institute for Health Research Oxford Biomedical Research Centre, and Open Philanthropy.

### **The Lancet Child & Adolescent Health**

Jan 2024 Volume 8 Number 1 p1-84

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

### **Lancet Digital Health**

Jan 2024 Volume 6 Number 1 e1-e86

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

### **Lancet Global Health**

Jan 2024 Volume 12 Number 1 e1-e169

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

### **Lancet Infectious Diseases**

Jan 2024 Volume 24 Number 1 p1-106, e1-e69

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

### **Lancet Public Health**

Jan 2024 Volume 9 Number 1 e1-e67

<https://www.thelancet.com/journals/lanpub/issue/current>

[New issue; No digest content identified]



## **Lancet Respiratory Medicine**

Jan 2024 Volume 12 Number 1 p1-88

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

## **Maternal and Child Health Journal**

Volume 27, issue 12, December 2023

<https://link.springer.com/journal/10995/volumes-and-issues/27-12>

[Reviewed earlier]

## **Medical Decision Making (MDM)**

Volume 44 Issue 1, January 2024

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

## **The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 101, Issue 3 Pages: 637-998 September 2023

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

## **Molecular Therapy**

Jan 03, 2024 Volume 32 Issue 1 p1-260

<https://www.cell.com/molecular-therapy/current>

[Reviewed earlier]

## **Nature**

Volume 626 Issue 7997, 1 February 2024

<https://www.nature.com/nature/volumes/625/issues/7997>

*Editorial* 30 Jan 2024

### **[Research funders must join the fight for equal access to medicines](#)**

Pandemic treaty is a rare opportunity to ensure pandemic-related technologies are accessible and affordable to all.

*Editorial* 31 Jan 2024

### **[How can scientists make the most of the public's trust in them?](#)**

Researchers have a part to play in addressing concerns about government interference in science.

*Article* Open Access 20 Dec 2023

### **[Digital measurement of SARS-CoV-2 transmission risk from 7 million contacts](#)**

Digital measurements of proximity and duration of exposure by the NHS COVID-19 app show a strong relation to actual infections among 7 million contacts notified in England and Wales, with longer durations translating to increased risk of transmission.

Luca Ferretti, Chris Wymant, Christophe Fraser

## **Nature Biotechnology**

Volume 42 Issue 1, January 2024

<https://www.nature.com/nbt/volumes/42/issues/1>

[Reviewed earlier]

### **Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 03 Feb 2024)

[No new digest content identified]

### **Nature Genetics**

Volume 56 Issue 1, January 2024

<https://www.nature.com/ng/volumes/56/issues/1>

[Reviewed earlier]

### **Nature Human Behaviour**

Volume 8 Issue 1, January 2024

<https://www.nature.com/nathumbehav/volumes/8/issues/1>

*Editorial*

Published: 25 January 2024

#### **[Promoting reproduction and replication at scale](#)**

*Nature Human Behaviour is partnering with the Institute for Replication for the large-scale reproduction and replication of our published research.*

Over the past fifteen years, there has been a substantial — and much needed — focus on rigour, reproducibility and replicability in science. Concerns that the majority of published research may be false<sup>1</sup> forced a reckoning in the research community and the next decade saw concerted efforts to identify and quantify the extent and impact of questionable research practices, publication bias, limited power and lack of transparency in reporting<sup>2</sup>. Replication efforts became highly visible — frequently with discouraging results (for example, ref. <sup>3</sup>) — and the priorities of the research community have been fundamentally altered.

*Article* Open Access 16 Oct 2023

#### **[A model of conceptual bootstrapping in human cognition](#)**

Zhao et al. present a model of conceptual bootstrapping through which they model learning complex concepts by recursively combining simpler concepts.

Bonan Zhao, Christopher G. Lucas, Neil R. Bramley

### **Nature Medicine**

Volume 30 Issue 1, January 2024

<https://www.nature.com/nm/volumes/30/issues/1>

[Reviewed earlier]

### **Nature Reviews Drug Discovery**

Volume 23 Issue 1, January 2024

<https://www.nature.com/nrd/volumes/23/issues/1>

[Reviewed earlier]

## **Nature Reviews Genetics**

Volume 25 Issue 1, January 2024

<https://www.nature.com/nrg/volumes/25/issues/1>

[Reviewed earlier]

## **Nature Reviews Immunology**

Volume 24 Issue 1, January 2024

<https://www.nature.com/nri/volumes/24/issues/1>

[Reviewed earlier]

## **New England Journal of Medicine**

February 1, 2024 Vol. 390 No. 5

<https://www.nejm.org/toc/nejm/medical-journal>

*Perspective*

### **[Recognizing Historical Injustices in Medicine and the Journal: Explaining Health Inequities — The Enduring Legacy of Historical Biases](#)**

D.S. Jones, E. Hammonds, J.P. Gone, and D. Williams

*Original Articles*

### **[Live, Attenuated, Tetravalent Butantan–Dengue Vaccine in Children and Adults](#)**

E.G. Kallás and Others

Butantan–Dengue Vaccine (Butantan-DV) is an investigational, single-dose, live, attenuated, tetravalent vaccine against dengue disease, but data on its overall efficacy are needed...

A single dose of Butantan-DV prevented symptomatic DENV-1 and DENV-2, regardless of dengue serostatus at baseline, through 2 years of follow-up. (Funded by Instituto Butantan and others; DEN-03-IB ClinicalTrials.gov number, [NCT02406729](#). opens in new tab, and WHO ICTRP number, [U1111-1168-8679](#). opens in new tab.)

*Editorials*

### **[Three Dengue Vaccines — What Now?](#)**

S.B. Halstead

## **njp Vaccines**

<https://www.nature.com/njpvaccines/>

[Accessed 03 Feb 2024]

[No new digest content identified]

## **Pediatrics**

Volume 153, Issue 2 February 2024

<https://publications.aap.org/pediatrics/issue/153/2>

*Articles*

### **[COVID-19 Vaccine Effectiveness Among Adolescents](#)**

[Eero Poukka, MD;](#)

*From the American Academy of Pediatrics*

*Policy Statement*

### **[Recommended Childhood and Adolescent Immunization Schedule: United States, 2024](#)**

[COMMITTEE ON INFECTIOUS DISEASES](#)

## **Pharmacoeconomics**

Volume 42, Issue 2 February 2024

<https://link.springer.com/journal/40273/volumes-and-issues/42-2>

Articles

### **[Cost-Effectiveness Analysis of Vaccines for COVID-19 According to Sex, Comorbidity and Socioeconomic Status: A Population Study](#)**

Javier Mar, Oliver Ibarondo, Maíra Aguiar

Original Research Article Open access 01 November 2023 Pages: 219 - 229

## **PLoS Biology**

<https://journals.plos.org/plosbiology/>

(Accessed 03 Feb 2024)

[No new digest content identified]

## **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 03 Feb 2024)

[No new digest content identified]

## **PLoS Global Public Health**

[https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\\_NEWEST\\_FIRST&filterStartDate=2021-10-01&filterJournals=PLOGlobalPublicHealth&q=&resultsPerPage=60](https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOGlobalPublicHealth&q=&resultsPerPage=60)

(Accessed 03 Feb 2024)

### **[Factors associated with COVID-19 vaccine uptake and hesitancy among healthcare workers in the Democratic Republic of the Congo](#)**

Michel K. Nzaji, Jean de Dieu Kamenga, Christophe Luhata Lungayo, Aime Cikomola Mwana Bene, Shanice Fezeu Meyou, Anselme Manyong Kapit, Alanna S. Fogarty, Dana Sessoms, Pia D. M. MacDonald, Claire J. Standley, Kristen B. Stolka

Research Article | published 01 Feb 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0002772>

## **PLoS Medicine**

<http://www.plosmedicine.org/>

(Accessed 03 Feb 2024)

[No new digest content identified]

## **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 03 Feb 2024)

[No new digest content identified]

## **PLoS One**

<http://www.plosone.org/>

[Accessed 03 Feb 2024]

**[Knowledge, attitude and perception towards COVID-19 among representative educated sub-Saharan Africans: A cross-sectional study during the exponential phase of the pandemic](#)**

Aniefiok John Udoakang, Nora Nghochuzie Nganyewo, Alexandra Lindsey Djomkam Zune, Charles Ochieng' Olwal, Nsikak-Abasi Aniefiok Etim, Mary Aigbiremo Oboh, Kesego Tapela, Francis Dzabeng, Samuel Mawuli Adadey, Agnes Udoh, Mazo Koné, Joe Kimanthi Mutungi, Peter Kojo Quashie, Gordon Akanzuwine Awandare, Lily Paemka  
Research Article | published 01 Feb 2024 PLOS ONE  
<https://doi.org/10.1371/journal.pone.0281342>

**PLoS Pathogens**

<http://journals.plos.org/plospathogens/>  
[Accessed 03 Feb 2024]  
[No new digest content identified]

**PNAS - Proceedings of the National Academy of Sciences of the United States**

January 30, 2024 vol. 121 no. 5  
<https://www.pnas.org/toc/pnas/121/5>  
[New issue; No digest content identified]

**PNAS Nexus**

Volume 3, Issue 1, January 2024  
<https://academic.oup.com/pnasnexus/issue/3/1>  
[New issue; No digest content identified]

**Prehospital & Disaster Medicine**

Volume 38 - Issue 6 - December 2023  
<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>  
[Reviewed earlier]

**Preventive Medicine**

Volume 178 January 2024  
<https://www.sciencedirect.com/journal/preventive-medicine/vol/178/suppl/C>  
[Reviewed earlier]

**Proceedings of the Royal Society B**

31 January 2024 Volume 291 Issue 2015  
<https://royalsocietypublishing.org/toc/rspb/current>  
*Commentary*

**[Transparent transmission models for informing public health policy: the role of trust and generalizability](#)**

Sophie L. Larsen and Alicia N. M. Kraay  
Published: 24 January 2024 Article ID: 20232273

**Public Health**

Volume 226 Pages e1-e6, 1-274 (January 2024)  
<https://www.sciencedirect.com/journal/public-health/vol/226/suppl/C>  
[Reviewed earlier]

### **Public Health Ethics**

Volume 16, Issue 2, July 2023  
<http://phe.oxfordjournals.org/content/current>  
[Reviewed earlier]

### **Public Health Genomics**

2023, Vol. 26, No. 1  
<https://karger.com/phg/issue/26/1>  
[Reviewed earlier]

### **Public Health Reports**

Volume 139 Issue 1, January/February 2024  
<https://journals.sagepub.com/toc/phrg/139/1>  
[Reviewed earlier]

### **Qualitative Health Research**

Volume 34 Issue 3, February 2024  
<https://journals.sagepub.com/toc/QHR/current>  
[Reviewed earlier]

### **Research Ethics**

Volume 20 Issue 1, January 2024  
<http://journals.sagepub.com/toc/reab/current>  
[Reviewed earlier]

### **Reproductive Health**

<http://www.reproductive-health-journal.com/content>  
[Accessed 03 Feb 2024]  
[No new digest content identified]

### **Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

2 Feb 2024

[Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension](#)

Special report | Spanish |

22 Jan 2024

[Neonatal mortality in countries of the Americas, 2000–2020: trends, inequalities, and target-setting](#)

Original research | English |

### **Risk Analysis**

Volume 44, Issue 1 Pages: 1-280 January 2024  
<https://onlinelibrary.wiley.com/toc/15396924/current>  
[Reviewed earlier]

### **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>  
[Accessed 03 Feb 2024]  
[Reviewed earlier]

### **Science**

Volume 383| Issue 6681| 26 Jan 2024  
<https://www.science.org/toc/science/current>  
*Editorial*

#### **Earning respect and trust**

BY H. Holden Thorp  
01 Feb 2024

Respect for, and trust in, science may be at an all-time low. In the United States, a 2023 Pew Research poll showed that only 57% of the population believed science has had a positive impact on society, and a Gallup poll showed that confidence in higher education was down to 36%. If the Gallup poll were done now, support would likely be even lower, given recent events with university presidents, from questions about their research integrity to their explanations for policies on student speech. I'm frequently asked what can be done about all of this, especially in the realm of science. Many scientists think the challenge has largely to do with science communication, which is certainly important. But first, the scientific community must begin to conduct itself in the same manner that it is asking of the public, and that means treating everyone in the scientific community with respect...

### **Science and Engineering Ethics**

Volume 30, Issue 1 February 2024  
<https://link.springer.com/journal/11948/volumes-and-issues/30-1>  
[New issue; No digest content identified]

### **Science Translational Medicine**

Volume 16| Issue 732| 31 Jan 2024  
<https://www.science.org/toc/stm/current>  
[New issue; No digest content identified]

### **Scientific Reports**

<https://www.nature.com/srep/articles?type=article>  
[Accessed 03 Feb 2024]  
[No new digest content identified]

### **Social Science & Medicine**

Volume 340 January 2024

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/340/suppl/C>

[Reviewed earlier]

### **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 03 Feb 2024]

[No new digest content identified]

### **Theoretical Medicine and Bioethics**

Volume 44, Issue 6 December 2023

<https://link.springer.com/journal/11017/volumes-and-issues/44-6>

[Reviewed earlier]

### **Travel Medicine and Infectious Diseases**

Volume 57 January–February 2024

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/57/suppl/C>

[Reviewed earlier]

### **Tropical Medicine & International Health**

Volume 29, Issue 1 Pages: i-iv, 1-71 January 2024

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

### **Vaccine**

Volume 42, Issue 3 Pages 403-722 (25 January 2024)

<https://www.sciencedirect.com/journal/vaccine/vol/42/issue/3>

*Short communication Abstract only*

#### **[Estimating county-level vaccination coverage using small area estimation with the National Immunization Survey-Child](#)**

Zachary H. Seeskin, Nadarajasundaram Ganesh, Poulami Maitra, Peter Herman, ... Seth Meador  
Pages 418-425

*Review article Abstract only*

#### **[Do vaccines increase or decrease susceptibility to diseases other than those they protect against?](#)**

Alberto Rubio-Casillas, Cesar Manuel Rodriguez-Quintero, Elrashdy M. Redwan, Munishwar Nath Gupta, ... Mikolaj Raszek  
Pages 426-440

*Review article Abstract only*

#### **[The Social Ecology of Health Beliefs and Misinformation Framework: Examining the impact of misinformation on vaccine uptake through individual and sociological factors](#)**

Joy C. Enyinnaya, Ashley A. Anderson, Nicole C. Kelp, Marilee Long, Colleen G. Duncan  
Pages 455-463

*Research article Open access*



**[Longitudinal assessment of an Ebola vaccine trial understanding among healthcare providers in the Democratic Republic of the Congo](#)**

Trésor Zola Matuvanga, Ynke Larivière, Gwen Lemey, Bernard Isekah Osang'ir, ... Pierre Van Damme  
Pages 481-488

*Research article Open access*

**[Vaccination equity and the role of community pharmacy in the United States: A qualitative study](#)**

Joni C. Carroll, Sophia M.C. Herbert, Thai Q. Nguyen, Caleb J. Schork, ... Catherine B. Rebitch  
Pages 564-572

*Research article Open access*

**[Determinants of immunization in polio super high-risk union councils of Pakistan](#)**

Ahmad Khan, Imtiaz Hussain, Dale A. Rhoda, Muhammad Umer, ... Sajid Bashir Soofi  
Pages 583-590

*Research article Open access*

**[National immunization technical advisory groups \(NITAGs\) in the WHO Eastern Mediterranean Region \(EMR\): A decade of shaping immunization policies, 2010–2021](#)**

Gerald Etapelong Sume, Hasan Quamrul, Sharifuzzaman Md, John Kissa, Yvan Hutin  
Pages 629-635

*Research article Open access*

**[Factors associated with parental Human Papillomavirus \(HPV\) vaccination intention of daughter: A national survey in Finland](#)**

Idil Hussein, Simopekka Vänskä, Jonas Sivelä, Tuija Leino, Hanna Nohynek  
Pages 701-712

## **Vaccines**

<https://www.mdpi.com/journal/vaccines>

[Accessed 03 Feb 2024]

*Latest Articles [Selected]*

*Open Access Article*

**[Assessing Vaccination Delivery Strategies for Zero-Dose and Under-Immunized Children in the Fragile Context of Somalia](#)**

by [Ahmed Said Bile](#), et al.

Vaccines 2024, 12(2), 154; <https://doi.org/10.3390/vaccines12020154> - 01 Feb 2024

*Abstract*

Somalia is one of 20 countries in the world with the highest numbers of zero-dose children. This study aims to identify who and where zero-dose and under-vaccinated children are and what the existing vaccine delivery strategies to reach zero-dose children in Somalia...

## **Value in Health**

February 2024 Volume 27 Issue 2 p133-270

<https://www.valueinhealthjournal.com/current>

*ECONOMIC EVALUATION*

**[Cost-Effectiveness of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the United States](#)**

Josh Carlson, et al.

Published online: December 01, 2023

p164-172

*Open Access*

## **World Development**

Volume 175 March 2024

<https://www.sciencedirect.com/journal/world-development/vol/175/suppl/C>

[Reviewed earlier]

.....  
.....

### ***Contents [click to move among sections]***

:: [\*Milestones, Perspectives\*](#)

:: [\*WHO\*](#)

:: [\*Organization Announcements\*](#)

:: [\*Journal Watch\*](#)

:: [\*Pre-Print Servers\*](#)

.....  
.....

### ***Pre-Print Servers***

#### **Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 03 Feb 2024]

*Selected Research*

[No new digest content identified]

#### **medRxiv**

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 03 Feb 2024]

[Filter: All articles]

#### **[Vaccination in metropolitan areas: Should the capital be prioritized in vaccine allocation?](#)**

Lucas Machado Moschen, Maria Soledad Aronna

medRxiv 2024.01.31.24302083; doi: <https://doi.org/10.1101/2024.01.31.24302083>

*Abstract*

This study presents a mathematical model for optimal vaccination strategies in interconnected metropolitan areas, considering commuting patterns. It is a compartmental model with a vaccination rate for each city, acting as a control function. The commuting patterns are incorporated through a weighted adjacency matrix and a parameter that selects day and night periods. The optimal control problem is formulated to minimize a functional cost that balances the number of hospitalizations and vaccines, including restrictions of a weekly availability cap and an application capacity of vaccines per unit of time. The key findings of this work are bounds for the basic reproduction number, particularly in the case of a metropolitan area, and the study of the optimal control problem. Theoretical analysis and numerical simulations provide insights into disease dynamics and the effectiveness of control measures. The research highlights the importance of prioritizing vaccination in the capital to better control the disease spread, as we depicted in our numerical simulations. This

model serves as a tool to improve resource allocation in epidemic control across metropolitan regions.

### [SARS-CoV-2 sequencing with cloud-based analysis illustrates expedient co-ordinated surveillance of viral genomic epidemiology across six continents](#)

Daniel Amoako, Nguyen To Anh, Jasmine Bastable, Marc Brouard, Constanza Campano Romero, Andres Castillo Ramirez, Bede Constantinides, Derrick Crook, Phan Manh Cuong, Moussa Moise Diagne, Amadou Diallo, Nguyen Thanh Dung, Laura Dunn, Le Van Duyet, Josie Everatt, Katherine Fletcher, Philip Fowler, Mailie Gall, Jessica Gentry, Saheer Gharbia, Hospital for Tropical Diseases SARS-CoV-2 testing team, Nguyen Thi Thu Hong, Martin Hunt, Zamin Iqbal, Katie Jeffery, Dikeledi Kekana, Thomas Kesteman, Jeff Knaggs, Marcela Lopes Alves, Dinh Nguyen Huy Man, Amy Mathers, Nghiem My Ngoc, Sarah Oakley, Hardik Parikh, Tim Peto, Marcelo Rojas Herrera, Nicholas Sanderson, Vitali Sintchenko, Jeremy Swann, Nguyen Thi Tam, Le Van Tan, Pham Ngoc Thach, Ndeye Marieme Top, Nguyen Thu Trang, Van Dinh Trang, H. Rogier Van Doorn, Anne von Gottberg, Nicole Wolter, Bernadette C Young  
medRxiv 2023.11.27.23298986; doi: <https://doi.org/10.1101/2023.11.27.23298986> **Revision**

### **OSF Pre-prints**

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]

***We observe increasing levels of "posting pollution" by individuals, sometimes posting 10+ items of no value. We will resume selective monitoring beginning in September.***

### **Wellcome Open Research**

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 03 Feb 2024]

*Selected Research*

*Review Open Access*

[Clinical trials and their impact on policy during COVID-19: a review](#) [version 1; peer review: awaiting peer review]

Paul Glasziou, et al.

*Abstract*

Background

Of over 8,000 recorded randomised trials addressing COVID-19, around 80% were of treatments, and 17% have reported results. Approximately 1% were adaptive or platform trials, with 25 having results available, across 29 journal articles and 10 preprint articles.

Methods

We conducted an extensive literature review to address four questions about COVID-19 trials, particularly the role and impact of platform/adaptive trials and lessons learned.

Results

The key findings were:

*Q1. Social value in conducting trials and uptake into policy?* COVID-19 drug treatments varied substantially and changed considerably, with drugs found effective in definitive clinical trials replacing unproven drugs. Dexamethasone has likely saved ½-2 million lives, and was cost effective across a range of countries and populations, whereas the cost effectiveness of remdesivir is uncertain. Published economic and health system impacts of COVID-19 treatments were infrequent.

*Q2. Issues with adaptive trial designs.* Of the 77 platform trials registered, 6 major platform trials, with approximately 50 treatment arms, recruited ~135,000 participants with funding over \$100 million.

*Q3. Models of good practice.* Streamlined set-up processes such as flexible and fast-track funding, ethics, and governance approvals are vital. To facilitate recruitment, simple and streamlined research processes, and pre-existing research networks to coordinate trial planning, design, conduct and practice change are crucial to success.

*Q4. Potential conflicts to avoid?* When treating patients through trials, balancing individual and collective rights and allocating scarce resources between healthcare and research are challenging. Tensions occur between commercial and non-commercial sectors, and academic and public health interests, such as publication and funding driven indicators and the public good.

Conclusion

There is a need to (i) reduce small, repetitive, single centre trials, (ii) increase coordination to ensure robust research conducted for treatments, and (iii) a wider adoption of adaptive/platform trial designs to respond to fast-evolving evidence landscape.

\* \* \* \*

### ***Think Tanks***

**Brookings** [to 03 Feb 2024]

<http://www.brookings.edu/>

*Research*

*No new digest content identified.*

**Center for Global Development** [to 03 Feb 2024]

<https://www.cgdev.org/>

*All Research [Selected]*

*POLICY PAPERS*

**[A New Playbook for Gavi: Advancing Equitable and Sustainable Immunization in an Evolving Global Landscape](#)**

Orin Levine et al.

January 30, 2024

For nearly 25 years, Gavi has delivered impact and value for money and remained one of the most successful global health initiatives. Gavi's success has been driven by its use of three primary levers: (1) accelerating new vaccine introductions, (2) increasing equitable immunization coverage, and...

**Chatham House** [to 03 Feb 2024]

<https://www.chathamhouse.org/>

*Selected Analysis, Comment, Events*

*No new digest content identified.*

**Council on Foreign Relations** [to 03 Feb 2024]

<https://www.cfr.org/media/news-releases>

*New Releases [Selected]*

*No new digest content identified.*

**CSIS** [to 03 Feb 2024]

<https://www.csis.org/>

*Reports [Selected]*

*No new digest content identified.*

**Kaiser Family Foundation** [to 03 Feb 2024]

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)  
*Newsroom*

*No new digest content identified.*

**McKinsey Global Institute** [to 03 Feb 2024]

<https://www.mckinsey.com/mgi/overview>  
*Latest Research*

*No new digest content identified.*

**ODI [Overseas Development Institute]** [to 03 Feb 2024]

<https://odi.org/en/publications/>  
*Publications [Selected]*

*No new digest content identified.*

**Pew Research Center** [to 03 Feb 2024]

<https://www.pewresearch.org/>  
*Latest Publications [Selected]*

*No new digest content identified.*

**Rand** [to 03 Feb 2024]

<https://www.rand.org/pubs.html>  
*Published Research [Selected]*

*No new digest content identified.*

**Urban Institute** [to 03 Feb 2024]

<https://www.urban.org/publications>

[\*\*New Research Publications - Selected\*\*](#)

*Research Report*

[\*\*A Blueprint for Promoting Equitable Health and Health Care through Community-Led Initiatives\*\*](#)

February 1, 2024

**World Economic Forum** [to 03 Feb 2024]

<https://agenda.weforum.org/press/>  
*Media [Selected]*

*No new digest content identified.*

.....

.....

**Public Consultations/Call for Inputs/Call for Papers**

## **Declaration of Helsinki – Phase I Public Comment Period**

World Medical Association

In order to maximize input by all stakeholders and the public, we are providing two separate public comment periods. A phase 1 public comment period is being held now to address issues from the first few regional meetings, and a phase 2 comment period will follow in the spring when additional topics have been addressed.

Open Now: Phase 1 Public Comment Period **Due: 7 February 2024.**

The workgroup's proposed edits to date are now available for public comment. To submit your or your organization's feedback, download the [phase 1 public comment document](#)

## **Call for Papers: Establishing the impact of WHO's normative and standard-setting functions: a call for papers**

WHO - Bull World Health Organ. 2023 Oct 1; 101(10): 618–618A. Published online 2023 Oct 1.

**The deadline for submissions is 1 March 2024**

*Editorial*

Lisa M Askie<sup>a</sup>, Rebekah AL Thomas<sup>a</sup>, Rok Ho Kim<sup>a</sup>, Mubashar Sheikh<sup>a</sup>, Jeremy Farrar<sup>b</sup>

doi: 10.2471/BLT.23.290829 PMID: PMC10523809

Normative leadership is a core function of the World Health Organization's (WHO) mandate, as outlined in its founding principles.<sup>1</sup> This leadership role is realized by developing evidence-based and ethically sound guidelines as well as other normative products that guide Member States in their public health decisions and actions, and by ensuring their recommendations are implemented.<sup>2</sup> WHO exercises its capacity for normative leadership to influence the development of legal norms and health policy and practice within its Member States...

... In the past five years, WHO has initiated a major change process, driven by its current Thirteenth Global Programme of Work,<sup>6</sup> the transformation agenda, and the need to respond to major global events including the coronavirus disease 2019 (COVID-19) pandemic and other crises. More recently, WHO has developed a comprehensive strategy to enhance its capacities and capabilities at country level, to ensure that its normative work drives measurable impact for all people more effectively.

Despite these initiatives, to date it is unclear whether these changes have improved WHO's credibility and impact as a normative organization. Questions remain as to how successful WHO's normative leadership role has been, how it can be further strengthened and how the impact of WHO's work in countries should be measured and rated in the future. The recent COVID-19 pandemic exposed both the strengths of and the challenges to WHO's normative leadership and global reach. While realizing the crucial role of WHO as a key directing and coordinating authority, the global health community has also witnessed the unprecedented rise of misinformation and mistrust in science.

Considering the spotlight on WHO's global normative leadership role during the pandemic,<sup>7</sup> and looking to prepare for future threats such as the health effects of climate change and ongoing conflict situations, the Bulletin of the World Health Organization calls for papers to help shape and inform WHO's mandate going forward. Topics of interest include: where has WHO succeeded in its normative leadership role? In what specific areas has it successfully shaped global health, and why were these initiatives successful? Where has WHO normative guidance been less impactful? If so, why was this the case, and what lessons can be learnt to improve impact in the future? What does the future of WHO's normative function look like, particularly in the context of digital technology and artificial intelligence? What aspects of the Organization's mandate, structure, function and administration need to be further strengthened or changed?

The Bulletin welcomes contributions from all stakeholders including public health decision-makers, researchers, and civil society and community representatives. Articles that propose innovative but

feasible ways by which WHO can further strengthen its normative leadership and guidance role, are encouraged.

\* \* \* \*  
\* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

*Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

\* \* \* \*  
\* \* \* \*